Clinical Trial Update: Sintilimab Plus Bevacizumab Biosimilar as Neoadjuvant Therapy for Resectable Hepatocellular Carcinoma [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating sintilimab plus a bevacizumab biosimilar as neoadjuvant therapy for resectable hepatocellular carcinoma; recruitment is ongoing.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• Bevacizumab biosimilar (Bevacizumab)
• Sintilimab (sintilimab)

Snippet

Sponsor: Sun Yat-sen University | Conditions: Hepatocellular Carcinoma, Neoadjuvant Therapy | Phase 2 | Status: RECRUITING